Belgian pharmaceutical maker Janssen-Cilag will eliminate 688 jobs, the company said Tuesday, as it seeks to put more money into research and development, and as exclusive patent rights to top-selling drugs expire.
The job cuts come less than two months after US parent company Johnson & Johnson said it would reduce its global work force by up to 4%, or up to 4,820 jobs, due to slumping sales of heart stents, its No. 2 anemia drug, Procrit, and looming patent expirations.
Janssen spokesman Stefaan Gijssels said the Belgian unit's decision to cut support services was prompted by the need to focus on research and a shift to more "volume-based" sales.
"We need money to invest in research. Costs in research are increasing rapidly," he said.
Shedding 521 permanent employees and 167 temporary contractors from plants in Beerse and Geel would help the company shave 15 percent off its costs, he said.
Janssen employs 4,723 people in Belgium with over a thousand working for the unit elsewhere in the world.
More
The job cuts come less than two months after US parent company Johnson & Johnson said it would reduce its global work force by up to 4%, or up to 4,820 jobs, due to slumping sales of heart stents, its No. 2 anemia drug, Procrit, and looming patent expirations.
Janssen spokesman Stefaan Gijssels said the Belgian unit's decision to cut support services was prompted by the need to focus on research and a shift to more "volume-based" sales.
"We need money to invest in research. Costs in research are increasing rapidly," he said.
Shedding 521 permanent employees and 167 temporary contractors from plants in Beerse and Geel would help the company shave 15 percent off its costs, he said.
Janssen employs 4,723 people in Belgium with over a thousand working for the unit elsewhere in the world.
More
No comments:
Post a Comment